World AIDS Day 2022

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by examining Central Nervous System pathogens that can cause AIDS.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by examining how various pathogens cause a variety of central nervous system (CNS) dysfunctions and the mechanisms of these changes.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing the interplay between HIV infection and the immune system, the mechanisms it can generate autoimmunity, and an overview of the primary autoimmune diseases commonly diagnosed in patients with HIV infection.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by describing the history of AIDS.

Sleep health is a good indicator to a person’s overall health status and general well-being. Proper sleep is one of the most important factors to healthy immunity. Protecting and restoring sleep quality are vital to well-being. Problems such as insomnia, obstructive sleep apnea, fatigue, and hypersomnia can all affect the quality of a person’s sleep.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by providing an overview of the viruses responsible for immunodeficiency syndromes like AIDS, highlighting their mechanism of action and targets for therapy.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by highlighting this unique role that HIV MTCT plays in understanding the immune correlates of protection and provide an overview of key aspects of MTCT including the epidemiology, transmission, and current prevention methods.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing the mechanisms of viral spread that are facilitated by cell–cell interactions and cell migration and discuss their implications for viral transmission, pathogenesis, and prevention.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing key advances in the field of neuropathogenesis and studies that have highlighted how molecular diversity within the HIV genome may impact HIV-associated neurologic disease.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by presenting a better understanding of how Nef disrupts antigen presentation may lead to the development of drugs that enhance the ability of the anti-HIV CTLs to control HIV disease.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by highlighting studies showing how HIV-1 uses exon definition to control the level of splicing at each of its 3′-splice sites.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by discussing current vaccine strategies for eliciting HIV-1 high mannose patch neutralizing antibodies.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by discussing insights into the regulation and induction of bnAbs based on the use of KI models.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by examining drivers of RIDS in treated HIV infection.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by covering transcription regulation of human immunodeficiency virus type 1 (HIV-1) gene expression, focusing on the invaluable contributions, made by HIV research over the years, toward the field of transcription.

This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by discussing the impact of chromatin structure on viral integration, transcriptional regulation and latency, and the host factors that influence HIV-1 replication by regulating chromatin organization.

Background: Inequalities undermine efforts to end AIDS by 2030. We examined socioeconomic inequalities in the 90–90–90 target among people living with HIV (PLHIV) —men (MLHIV), women (WLHIV) and adolescents (ALHIV). Methods: We analysed the available Population HIV Impact Assessment (PHIA) survey data for each of the 12 sub-Saharan African countries, collected between 2015 and 2018 to estimate the attainment of each step of the 90–90–90 target by wealth quintiles.

An Article in support of SDG 3, assessing whether community mobilisation increases HIV testing, linkage to care, and retention in care over time in intervention relative to control communities.

An Article in support of SDG 3, showing that in a sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality.

This Article supports SDG 3 by providing new insights on the degree and determinants of real-world PrEP effectiveness among men at risk of HIV in France, with relevance in the current context of worldwide PrEP scale up.

This Article supports SDG 3 by investigating the role of CD8+ T cell count on suppressive ART as a predictor of clinical progression in HIV, suggesting its potential use as a clinical biomarker in evaluations of novel therapies for ongoing immune dysfunction during treated infection.

Background: There are 15·4 million children who are HIV-exposed and uninfected worldwide. Early child development crucially influences later academic and socioeconomic factors. However, the neurodevelopmental outcomes of HIV-exposed uninfected (HEU) children in the era of maternal antiretroviral therapy (ART) remain unclear. We aimed to examine the effects of in-utero exposure to HIV and ART on child neurodevelopment.

This Article supports SDGs 3, 5, and 10 by evaluating the safety and efficacy of injectable cabotegravir versus daily oral tenofovir diphosphate plus emtricitabine for HIV prevention in HIV-uninfected women across sub-Saharan Africa.

An Article in support of SDG 3, evaluating conditions under which risk-informed pre-exposure prophylaxis use would be cost-effective in sub-Saharan Africa.

This Review supports SDG 3, systematically reviewing the availability of HIV-1 viral sequences from antiretroviral therapy naive and experienced people, because these sequences are important in understanding HIV-1 drug resistance.

This Review supports SDGs 3 and 6, focusing on the complex ways that multiple factors interact during droughts to influence HIV treatment adherence. The authors suggest that economic and livelihood challenges resulting from food and water insecurity during droughts have the biggest impact on adherence.

Overall survival has improved for patients with HIV and TCLs such as AIDS-defining B-cell lymphomas in the last decade. Low CD4 cell count predicts poor overall survival in patients with HIV and TCL, emphasizing the need for effective antiretroviral therapy.

This Series paper supports SDGs 3 and 10, reviewing the intersectionality of HIV-related stigma and ageing-related stigma with health-related quality of life, suggesting that the intersectionality of stigmas creates a new inequality that is greater than the individual components.

This Series paper supports SDG 3, examining hallmarks of ageing as drivers of multimobidity in people with HIV.

An Article in support of SDG 3, estimating the frequency of negative post-discharge outcomes, and assessing risk factors for such outcomes, in people with HIV.

To date, most cancer clinical trials exclude all HIV-infected patients. The HIV Working Group has defined important principles related to eligibility criteria for HIV-infected patients with cancer. Notably, patients with CD4 count $350/mL should generally be eligible for any study, whereas lower CD4 count may be appropriate in the setting of second-line and later cancer therapy, assuming cART is carefully managed. All these studies will require multidisciplinary efforts.

An Article in support of SDG 3, showing that universal HIV testing and treatment improved employment outcomes and other indicators of socioeconomic wellbeing for HIV-positive adults and children in their households, but had no effect on HIV-negative adults.

This Article supports SDGs 3 and 10, assessing whether people ageing with HIV have more drug-drug interactions than those without HIV, and whether this confers greater risk of hospitalisation.

An Article in support of SDG 3, assessing the current sex-specific HIV burden in 204 countries and territories and measuring progress in the control of the epidemic.

We conducted a retrospective multicenter international analysis to identify prognostic factors, survival, and treatment-related outcomes in patients with HIV-BL contemporaneously treated. In this large collaborative effort, we analyzed a cohort of 249 patients with newly diagnosed HIV-BL treated at 35 centers in the United States and United Kingdom.

This Viewpoint supports SDG 3 by exploring the reasons behind inadequate PrEP uptake to date and offering considerations for effective scale up to meet 2030 UNAIDS targets.

A investigation of how HIV spreads.

A Viewpoint article, in support of SDG 3, discussing how a therapeutic cure for HIV could address persistent unmet needs associated with current treatment and prevention strategies.

A Review, in support of SDGs 3 and 17, summarising the efforts of a target product profile working group formed after the Sunnylands Summit: The Path Toward Ending HIV, in Feb 7–9, 2019, to develop target product profiles for HIV curative interventions.

A Commission, in support of SDGs 3 and 17, assessing the future of the HIV response in the context of a more integrated approach to health.

We conducted a retrospective multicenter international analysis to identify prognostic factors, survival, and treatment-related outcomes in patients with HIV-BL contemporaneously treated. In this large collaborative effort, we analyzed a cohort of 249 patients with newly diagnosed HIV-BL treated at 35 centers in the United States and United Kingdom.